Information Provided By:
Fly News Breaks for May 11, 2015
INSM
May 11, 2015 | 07:46 EDT
Cowen raised its price target on Insmed to $25 from $20 following Q1 results, citing the company's continued execution and enrollment in its pivotal '212 Arikayce NTM study. The firm sees the chance of success of the study and opportunity for the drug as the major value driver for the company and reiterated its Outperform rating on Insmed shares.
News For INSM From the Last 2 Days
INSM
INSM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.